Replies to post #112525 on Biotech Values

[jq1234]

Keep in mind that, according to RIGL, the increased blood pressure typically only occurs during the first month of treatment. If a one-time adjustment in anti-hypertension medication is made at that time, there is no longer elevated blood pressure.

That's exactly why you can't just listen to what the company says. Look at the data, what they said was not entirely true - they always exeggerate benefit minimize risk:

From TASKi2:

The mean increase in blood pressure from baseline at 6 months, using a last observation carry forward methodology, was less than 0.5 mmHg for the 150 mg qd dose group and approximately 1 mmHg for the 100 mg bid dose group. Approximately 18% and 23% of patients in the 150 mg qd and the 100 mg bid dose groups, respectively, had blood pressure medication adjusted or in some cases initiated during the course of the study, compared with 7% of the placebo patients. The blood pressure was successfully reduced in these patients, and their blood pressure was generally well controlled throughout the trial. The blood pressure medications were standard doses of common blood pressure medications such as ACE inhibitors or diuretics.

Placebo 150mg qd 100mg bid
Mean Blood Pressure(Systolic/Diastolic in mmHg) Baseline 125/76 125/77 125/77
At Month 6 123/76 125/77 125/78
Change from Baseline to Month 6 (LOCF) -1.8/+0.4 +0.2/+0.3 +0.6/+1.4